Industry
Industry in One Page
ConvaTec lives inside a specific corner of medical devices: chronic-care consumables. The arena sells single-use products that patients with long-term conditions reorder for life — wound dressings for diabetic foot ulcers and surgical wounds, ostomy pouches for colorectal-cancer and IBD patients, intermittent catheters for spinal-cord-injury patients, and disposable infusion sets that connect insulin pumps to people with type 1 diabetes. The buyers are a barbell: hospitals and group purchasing organisations (GPOs) for acute episodes, and home-care patients funded by Medicare/Medicaid, private payers, and national health systems for the long tail. Profits exist because clinical evidence, regulator filings (FDA 510(k), EU MDR), and patient/clinician switching costs make even a "simple" pouch or dressing surprisingly defensible — but only the manufacturers with global scale, deep clinical files, and direct home-delivery footprints earn the high-twenties operating margins the best peers post.
The newcomer's most common mistake is treating this like high-growth medtech: it is not Insulet's Omnipod or DexCom's CGM. It is consumables: 4-7% organic growth, gross margins in the 50-70s, and the cycle that bites hardest is regulatory/reimbursement change, not patient volume.
Takeaway: the patient consumes, the HCP specifies, the distributor delivers, the payer pays — and the manufacturer captures profit only by being clinically preferred and logistically convenient. Lose either and a category goes commodity fast.
How This Industry Makes Money
This is a consumables-on-an-installed-base business. A patient becomes an ileostomate or starts an insulin pump once; from then on they reorder pouches, dressings, catheters, or infusion sets every 1-3 days for the rest of their life. Revenue is recurring even though products are nominally "single-use," and reorder rates inside an installed base run 90%+. Pricing is per-unit (per pouch, per dressing, per box of catheters, per set), often anchored to a reimbursement code rather than a list price.
The cost stack is unusual for medtech. Cost of goods is dominated by specialty polymers, medical-grade silicones, hydrocolloids, and adhesives, not silicon or precision components. That keeps gross margins in the 50-72% range across the peer set, but it also means raw-material inflation and tariffs flow through directly: ConvaTec's FY2026 guidance bakes in c.20 bps of incremental tariff cost in H1 alone. Below the line, the spending profile shifts to clinical evidence, regulatory filings, salesforce productivity, and home-delivery logistics. R&D runs roughly 3-5% of sales (CTEC reported $111M in FY2025, ~4.5% of revenue), but commercial spend is the bigger lever — wound nurses, stoma nurses, and endocrinologists each have to be educated on every new SKU.
Where the dollar goes - peer P&L stack, FY2025 reported
Takeaway: gross margin spread is wide (53-72%) and tracks product mix, not scale — Coloplast's pure ostomy/continence mix and Insulet's patented Omnipod earn ~70%+; ConvaTec and Solventum carry more wound/general-surgery mix and sit lower.
Where bargaining power sits in the chronic-care consumables chain
The two stages that matter most are the manufacturer (brand + clinical file + IP) and the payer. A favourable Local Coverage Determination (LCD) can lift a SKU from niche to billion-dollar overnight; a tightening LCD can vaporise a forecast. CMS's April 2025 postponement of the diabetic-foot-ulcer LCD that would have squeezed cellular and tissue products was a textbook example — ConvaTec's InnovaMatrix forecast went up the same week.
Demand, Supply, and the Cycle
This is one of the most defensive industries in medtech. Demand is anchored to chronic disease prevalence (diabetes, IBD, colorectal cancer, pressure injuries), which grew through every recession of the last 30 years. The global wound care market is forecast to grow from $22.2B in 2025 to $30.5B by 2030 at a 6.5% CAGR; the global ostomy care market sits at $3.5B in 2025 and is forecast to reach $4.3B by 2030 at a 4.4% CAGR; the NPWT (negative-pressure wound therapy) sub-segment is on track for $3.8B by 2030. None of those forecasts assume an economic recovery — they assume an aging population.
But the cycle does exist, and it bites in three places:
Demand and supply drivers - where the cycle hits first
The cycle shows up first in price, not volume. A patient who needs an ostomy pouch needs one whether GDP is up or down; what changes is whether CMS, NHS England, or German GKV decides to ratchet reimbursement. The second place is mix — premium dressings, biologics, and patented infusion sets are the first SKUs squeezed out when tenders tighten. Volume only flexes via deferred elective surgeries, and even there the rebound is reliable.
The asymmetry to remember: in chronic-care consumables, downside is shallow (volume rarely falls more than 3-5%) but recovery is slow (price concessions, once granted, stick). The opposite of cyclical industrial demand.
Competitive Structure
The arena is concentrated by sub-segment but globally fragmented. Each of CTEC's four franchises has a different competitor map.
Sub-segment concentration - each franchise has its own map
Two structural facts deserve emphasis. First, private competitors are first-rank: Mölnlycke (Investor AB), Hollister (employee-owned), Wellspect (Dentsply Sirona spin-back, then private), and B. Braun (Germany) are not in any peer-comp screen but are economic threats just as real as listed peers. Public valuations of CTEC, Coloplast, and SNN therefore reflect only part of the actual competitive structure. Second, the listed peers are not equivalent: SOLV (formerly 3M Health Care) is a $8B-revenue diversified medsurg/wound business; PODD ($2.7B revenue) is a tubeless-pump pure play that is the demand-side disruptor to CTEC's infusion-set franchise; IART ($1.6B) is a wound-recon biologics adjacency. The closest like-for-like is Coloplast, and even Coloplast skews more to ostomy/continence than CTEC.
Coloplast prints both the highest gross margin and the highest operating margin in the listed peer set — it is the structural benchmark for what a focused chronic-care consumables business can earn at scale. SOLV's FY2025 op margin reflects its post-spin cost base after 3M corporate allocations rolled off, not steady-state. IART's negative op margin is driven by an acquisition-related impairment.
Regulation, Technology, and Rules of the Game
External rules shape returns more than product innovation does. Five rule sets matter.
Rules of the game - what shapes economics, not buzzwords
Two technology shifts are real economic events, not vapour. GLP-1s lengthen the productive life of diabetic patients, which adds patient-years to the chronic-care installed base — counter-intuitively bullish for CTEC's infusion-set, wound, and continence franchises despite the "GLP-1 kills medtech" headline. Tubeless insulin pumps (Insulet's Omnipod) are the real disruptor: they bypass the infusion set entirely, so PODD's growth is the mirror image of CTEC Infusion Care's slowdown thesis. The split between tubed pumps (Tandem, Medtronic, Ypsomed — CTEC customers) and tubeless (Insulet — competitor) defines the segment's economics for the next decade.
The Metrics Professionals Watch
Generic ratios miss this industry. The metrics that explain value creation in chronic-care consumables are below — track these and you can read any earnings release in 60 seconds.
The 8 metrics professionals actually track
The single most important number is organic constant-currency revenue growth. Reported revenue blends FX, M&A, divestments, and one-offs (e.g., InnovaMatrix LCD timing). Strip all of that out and you see whether the franchise is genuinely winning share, holding it, or losing it. ConvaTec's step-up of its medium-term organic target to 6-8% (from 5-7%), reaffirmed at the 9 April 2026 Capital Markets Day, is the kind of step-change that matters more than any quarterly headline.
Where ConvaTec Group plc Fits
ConvaTec is a scaled mid-tier challenger in chronic-care consumables — large enough to defend, small enough to grow faster than the market leaders. Revenue of $2.44B (FY2025) puts it just behind Coloplast in the focused chronic-care space and well below diversified peers SOLV ($8.3B) and SNN ($6.2B). Its position is segment-specific:
Where ConvaTec fits, segment by segment
The structural read: ConvaTec is a classic chronic-care consumables compounder, not a high-growth medtech. The margin gap to Coloplast (operating margin 13% vs 26%) is the strategic prize — closing half of that gap defines the upside case. The risk is segment-specific: tubeless pumps disrupting Infusion Care, undifferentiated wound-care SKUs in tighter LCD environments, and the structural gap to Coloplast in ostomy share. Read Warren's Business tab next for moat depth and the Forensic tab for accounting around adjusted vs reported margins.
What to Watch First
A reader checking whether the industry backdrop is improving or deteriorating for ConvaTec should look at these signals first.
The 7 first-look signals - improving or deteriorating?
The single biggest near-term catalyst on this list is CMS reimbursement decisions for advanced wound care biologics. One ruling can move a 5-percentage-point segment growth rate up or down — the rest of the report's growth model rests on it.